Washington University University of Texas Southwestern VCID Consortium Site

项目总结 血管对认知损害和痴呆的贡献(VCID)是导致痴呆的第二大原因，也是导致阿尔茨海默病(AD)的主要因素，阿尔茨海默病(AD)是最常见的痴呆原因。非侵入性生物标志物对于制定VCID的预防和治疗策略至关重要。MarkVCID联盟的第一个赠款周期确定了11个候选成像和流体生物标记物。在第二个赠款周期(RFA-NS-21-005)中，VCID财团将“…对这11个生物标志物…中的最多6个进行全面的多点临床验证“为了响应这一RFA，华盛顿大学医学院和德克萨斯大学西南医学中心(WU-UTSW)之间建立了强有力的合作伙伴关系，作为小型船舶VCID财团的新地点。这两个机构都是大容量的三级护理转诊中心，为种族、民族、社会经济和城乡多样性的大城市地区提供服务。圣路易斯和达拉斯位于中风带内或邻近中风带--很大一部分人口是中风、脑血管疾病和VCID风险最高的人群。由于VCID处于脑血管风险和老年性痴呆症之间的交界处，这一合作伙伴关系利用了吴和UTSW现有的脑血管和阿尔茨海默病(AD)研究基础设施的优势。这两个机构都有活跃的AD研究中心，而Wu是StrokeNet的区域协调中心，展示了基于网络的协作临床研究的良好记录。此外，来自两个中心的研究人员正在积极领导几项涉及VCID或ADRD参与者的独立纵向临床研究。我们汇集了一批中风和AD临床医生、临床研究人员和科学家，他们在VCID和AD病理生物学、临床试验实施和管理、流体生物标记物收集和测量、磁共振图像采集和处理、信息学和数据共享以及统计学方面拥有不同的专业知识。吴-UTSW小组的集体专业知识不仅将使目前的VCID生物标记物研究得以实施，而且还将在完善VCID当前和未来生物标记物研究的设计方面提供独特的熟练程度。我们将通过以下目标实现VCID联盟的目标：目标1：招募和纵向跟踪VCID风险的不同参与者队列。目的2：纵向获取和重复性测量VCID队列中基于流体的生物标志物。目的3：纵向获取和重复处理VCID队列中基于MRI的生物标记物。

PROJECT SUMMARY Vascular contributions to cognitive impairment and dementia (VCID) are the second leading cause of dementia, and a major contributor to Alzheimer’s disease (AD), the most common cause of dementia. Non- invasive biomarkers are critical for the development of prevention and treatment strategies for VCID. The first grant cycle of the MarkVCID consortium identified 11 candidate imaging and fluid biomarkers. In this second grant cycle (RFA-NS-21-005), the VCID consortium will “…carry out comprehensive multi-site clinical validation of up to six of these 11 biomarkers….” In response to this RFA, a strong partnership between Washington University School of Medicine and the University of Texas, Southwestern Medical Center (WU-UTSW) has been developed to serve as a new site for the Small Vessel VCID Consortium. Both institutions are high-volume tertiary care referral centers that serve large metropolitan areas with racial, ethnic, socioeconomic, and urban/rural diversity. St. Louis and Dallas are located within or adjacent to the stroke belt—with significant portions of the population at the highest risk of stroke, cerebrovascular disease, and VCID. Because VCID sits at the interface between cerebrovascular risk and age-related dementia, this partnership leverages strengths in both the cerebrovascular and Alzheimer’s disease (AD) research infrastructures that already exist at WU and UTSW. Both Institutions have active AD research centers, and WU is a StrokeNet regional coordinating center, demonstrating a strong track record of collaborative network-based clinical studies. In addition, investigators from both centers are actively leading several independent longitudinal clinical studies that involve participants with VCID or ADRD. We have assembled a group of stroke and AD clinicians, clinical investigators, and scientists who have diverse expertise in VCID and AD pathobiology, clinical trials implementation and management, fluid biomarker collection and measurement, MR image acquisition and processing, informatics and data sharing, and statistics. The collective expertise of the WU-UTSW group will not only permit the implementation of the current VCID biomarker study but will also provide unique proficiencies in refining the design of the current and future biomarker studies for VCID. We will achieve the goals of the VCID consortium through the following aims: Aim 1: Recruit and longitudinally follow a diverse cohort of participants at risk for VCID. Aim 2: Longitudinally acquire and reproducibly measure fluid-based biomarkers for this VCID cohort. Aim 3: Longitudinally acquire and reproducibly process MRI-based biomarkers for the VCID cohort.